Citations

Clear

3138 citation(s) found for "Smith, AM".

Prognostic significance of haemodynamic parameters in patients with cardiogenic shock
Berg, David D. , Baird-Zars, Vivian M., Alviar, Carlos L. , Barsness, Gregory W. , Burke, James A. , Chonde, Meshe , Cooper, Howard A., Daniels, Lori B. , Dodson, Mark , Gidwani, Umesh , Goldfarb, Michael , Guo, Jianping , Hillerson, Dustin , Kenigsberg, Benjamin B. , Kochar, Ajar , Kontos, Michael C. , Lopes, Mathew S. , Loriaux, Daniel B. , Miller, P. Elliott , O’Brien, Connor , Papolos, Alexander , Patel, Siddharth M. , Pisani, Barbara , Prasad, Rajnish, Smith, Timothy D., Teuteberg, Jeffrey J. , Thompson, Andrea D. , Zakaria, Sammy , Katz, Jason N. , Goldfarb, Michael , Kochar, Ajar , Patel, Siddharth M , Solomon, Michael A , van Diepen, Sean , Goldfarb, Michael , Daniels, Lori B , Goldfarb, Michael , Berg, David , Thompson, Andrea , Zakaria, Sammy , Chonde, Meshe D , O'Brien, Connor G , Hillerson, Dustin , Kaur, Gurleen , Bohula, Erin A. , Barnett, Christopher F. , Burke, James A, Chaudhry, Sunit‐Preet , Gerber, Daniel , Ghafghazi, Shahab , Kwon, Younghoon, Potter, Brian J , Prasad, Rajnish, Roswell, Robert O. , Shah, Kevin S , Sinha, Shashank S , Solomon, Michael A. , Diepen, Sean van , Morrow, David A.

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | August 16, 2023 | Volume: 12 | Issue: 10 | Pages: 651-660

10.1093/ehjacc/zuad095 | PMID 37640029 Get It

Abstract Aims Invasive haemodynamic assessment with a pulmonary artery catheter is often used to guide the management of patients with cardiogenic shock (CS) and may provide important prognostic information. We aimed to assess prognostic associations and relationships to end-organ dysfunction of presenting haemodynamic parameters in CS. Methods and results The Critical Care Cardiology Trials Network is an investigator-initiated multicenter registry of cardiac intensive care units (CICUs) in North America coordinated by the TIMI Study Group. Patients with CS (2018–2022) who underwent invasive haemodynamic assessment within 24 h of CICU admission were included. Associations of haemodynamic parameters with in-hospital mortality were assessed using logistic regression, and associations with presenting serum lactate were assessed using least squares means regression. Sensitivity analyses were performed excluding patients on temporary mechanical circulatory support and adjusted for vasoactive-inotropic score. Among the 3603 admissions with CS, 1473 had haemodynamic data collected within 24 h of CICU admission. The median cardiac index was 1.9 (25th–75th percentile, 1.6–2.4) L/min/m2 and mean arterial pressure (MAP) was 74 (66–86) mmHg. Parameters associated with mortality included low MAP, low systolic blood pressure, low systemic vascular resistance, elevated right atrial pressure (RAP), elevated RAP/pulmonary capillary wedge pressure ratio, and low pulmonary artery pulsatility index. These associations were generally consistent when controlling for the intensity of background pharmacologic and mechanical haemodynamic support. These parameters were also associated with higher presenting serum lactate. Conclusion In a contemporary CS population, presenting haemodynamic parameters reflecting decreased systemic arterial tone and right ventricular dysfunction are associated with adverse outcomes and systemic hypoperfusion.
COVID‐19 and abortion in the Ohio River Valley: A case study of Kentucky, Ohio, and West Virginia
Smith, Mikaela H. , Broscoe, Molly, Hill, Jessie , Hood, Robert B. , McGowan, Michelle L. , Norris, Alison H. , McGowan, Michelle, Chakraborty, Payal , Bessett, Danielle

Mayo Clinic

Perspectives on Sexual and Reproductive Health | August 12, 2023 | Volume: 55 | Issue: 3 | Pages: 178-191

10.1363/psrh.12244 | PMID 37571959 Get It

AbstractIntroductionDuring early stages of COVID‐19 in the United States, government representatives in Kentucky, Ohio, and West Virginia restricted or threatened to restrict abortion care under elective surgery bans. We examined how abortion utilization changed in these states.MethodologyWe examined COVID‐19 abortion‐related state policies implemented in March and April 2020 using publicly available sources. We analyzed data on abortions by method and gestation and experiences of facility staff, using a survey of 14 facilities. We assessed abortions that took place in February–June 2020 and February–June 2021.ResultsIn February–June 2020 the monthly average abortion count was 1916; 863 (45%) were medication abortions and 229 (12%) were ≥14 weeks gestation. Of 1959 abortions performed across all three states in April 2020, 1319 (67%) were medication abortions and 231 (12%) were ≥14 weeks gestation. The shift toward medication abortion that took place in April 2020 was not observed in April 2021. Although the total abortion count in the three‐state region remained steady, West Virginia had the greatest decline in total abortions, Ohio experienced a shift from instrumentation to medication abortions, and Kentucky saw little change. Staff reported increased stress from concerns over health and safety and increased scrutiny by the state and anti‐abortion protesters.DiscussionAlthough abortion provision continued in this region, policy changes restricting abortion in Ohio and West Virginia resulted in a decrease in first trimester instrumentation abortions, an overall shift toward medication abortion care, and an increase in stress among facility staff during the early phase of COVID‐19.
Core outcomes in nerve surgery: development of a core outcome set for ulnar neuropathy at the elbow
Wilson, Thomas J. , Davis, Gavin A , Guedes, Fernando , Hébert‐Blouin, Marie‐Noëlle, Jack, Megan M. , Jacques, Line , Kretschmer, Thomas , Midha, Rajiv, Puffer, Ross C. , Rasulić, Lukas , Ray, Wilson Z. , Rizk, Elias , Rodríguez-Aceves, Carlos Alberto , Shapira, Yuval, Spinner, Robert J. , Zager, Eric L. , Davis, Gavin A. , Dengler, Nora F. , Mahan, Mark A , Pondaag, Willem , Smith, Brandon W. , Socolovsky, Mariano

Mayo Clinic

Journal of Neurosurgery | August 12, 2023 | Volume: 140 | Issue: 2 | Pages: 489-497

10.3171/2023.6.jns23702 | PMID 37877978 Get It

OBJECTIVE Ulnar neuropathy at the elbow (UNE) is common, affecting 1%–6% of the population. Despite this, there remains a lack of consensus regarding optimal treatment. This is primarily due to the difficulty one encounters when trying to assess the literature. Outcomes are inconsistently reported, which makes comparing studies or developing meta-analyses difficult or even impossible. Thus, there is a need for a core outcome set (COS) for UNE (COS-UNE) to help address this problem. The objective of this study was to utilize a modified Delphi method to develop COS-UNE. METHODS A 5-stage approach was utilized to develop COS-UNE: stage 1, consortium development; 2, literature review to identify potential outcome measures; 3, Delphi survey to develop consensus on outcomes for inclusion; 4, Delphi survey to develop definitions; and 5, consensus meeting to finalize the COS and definitions. The study followed the Core Outcome Set-STAndards for Development (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 21 participants, all neurological surgeons representing 11 countries. The final COS-UNE consisted of 22 data points/outcomes covering the domains of demographic characteristics, diagnostics, patient-reported outcomes, motor/sensory outcomes, and complications. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 6 months, with the consensus optimal timepoints for assessment identified as preoperatively and 3, 6, and 12 months postoperatively. CONCLUSIONS The authors identified consensus data points/outcomes and also provided definitions and specific scales to be utilized to help ensure that clinicians are consistent in their reporting across studies on UNE. This COS should serve as a minimum set of data to be collected in all future neurosurgical studies on UNE. The authors hope that clinicians evaluating ulnar neuropathy will incorporate this COS into routine practice and that future studies will consider this COS in the design phase.
Understanding the role of CD22 on Macrophage and Dendritic Cell Function
Zastrow, Alexi, Crotts, Sydney B. , Rajcula, Matthew, Hammer, B. W., Elissa, Mai, Friedman, David J. , Hammer, Brady, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 72.08-72.08

10.4049/jimmunol.210.supp.72.08 Get It

Abstract At the terminal position of many glycan chains are unique sugars known as sialic acids. Sialic acids bind sialic acid immunoglobin-like lectins (Siglecs). Our lab is interested in the role of CD22 (Siglec-2), which binds to α2,6-linked sialic acid generated by ST6GalI. CD22 can associate with itself or other molecules on the same cells in a “cis” configuration or bind in “trans” with ligands on other cells. CD22 contains four ITIMs within its cytoplasmic tail and is primarily known to function as an inhibitory co-receptor of the B cell receptor (BCR). CD22-ligand interactions restrain CD22 and BCR association which dampens BCR signaling. While CD22 is usually characterized as a B cell specific protein, we found that CD22 is highly expressed in hybrid macrophages (CD11b+ CD11c+ F4/80+) and expression decreases with activation, implying that CD22 may modulate myeloid cell responses. Using novel macrophage and dendritic cell-specific CD22 cKO mouse models, we will explore how CD22 impacts myeloid cell activation. We propose that CD22 impacts myeloid cell function and modulating this interaction may improve immune responses.
The role of ST8Sia6 in braking inflammation in Inflammatory Bowel Disease
Crotts, Sydney B. , Antonetti, Regina, Shapiro, Michael J. , Rajcula, Matthew, Hammer, Brady, Mai, Elissa, Shapiro, Michael, Hammer, Brady, Mai, Elissa, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 170.08-170.08

10.4049/jimmunol.210.supp.170.08 Get It

Abstract Inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn’s disease (CD) affects between 1–3 million people in the United States and costs an estimated $11–28 billion in national healthcare costs. Patients present with symptoms including diarrhea, rectal bleeding, and fatigue. Characterization of molecules that regulate IBD is critical in understanding pathogenesis. ST8Sia6 is a sialic acid transferase that adds terminal a2,8 disialic acids to cell surface glycoproteins, and we have found that ST8Sia6 knockout (KO) mice exhibit increased spontaneous small bowel (SB) lamina propria CD4 TH1 polarization, increased inflammatory cytokine production, decreased IgA class switching of SB plasma cells, and alterations of the SB innate lymphoid cells, indicative of gut inflammation. Moreover, adult ST8Sia6 KO mice have shortened small and large bowels, likely due to baseline inflammation. These mice do not exhibit overt baseline symptoms, but ST8Sia6 KO mice exhibit increased weight loss and decreased survival when challenged with dextran sodium sulfate (DSS)-induced colitis, which was also enhanced when co-housed with wildtype (WT) mice. DSS-challenged ST8Sia6 KO mice exhibit increased histological damage and immune infiltration of the gut as compared to WT controls. Accelerated DSS-induced colitis is also observed when ST8Sia6-deficient bone marrow is transplanted into WT recipients, indicating that the effect is mediated specifically by immune cells. This data demonstrates a role for ST8Sia6 in regulating the host immune response to IBD, and further elucidating this role will aid in developing a mechanistic understanding of IBD pathogenesis and in understanding potential immunotherapies for the disease. R01CA243545, 5T32DK124190-03
Defining the Role of HDAC3 Deacetylation and Decrotonylation in T Cells
Martinez, Kodi, Shapiro, Michael J. , Rajcula, Matthew, Hammer, Brady, Mai, Elissa, Shapiro, Michael, Lee, Hyun Se Kim , Hammer, Brady, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 219.10-219.10

10.4049/jimmunol.210.supp.219.10 Get It

Abstract Histone acetyltransferases (HATs) and histone deacetylases (HDACs) facilitate addition or removal of various acyl groups from lysine residues, including acetylation (KAc) and crotonylation (KCr). Recently, mutations in p300 and CBP were identified that abrogate their function as an acetyltransferase but not the ability to mediate crotonylation. These mutants can activate transcription independent of their ability to acetylate histones, demonstrating that crotonylation can also lead to transcriptional activation. The Class I deacetylases HDAC1, HDAC2, and HDAC3 have been shown to have both decrotonylase and deacetylase activity, but the relative importance of each function in T cells is not known. Genetic knockout of HDAC3 using CD2 icre mice results in a severe block in T cell development and spontaneous development of severe colitis. Examination of HDAC3 cKO mice has shown an aberrant ratio of Treg:Th17 cells within the gut, driving inflammation and loss of mucosal barrier integrity. Our lab has also determined that HDAC3 is required for at least three aspects of T cell development: CD4+ CD8+ (DP) cell survival, positive selection, and CD4+ lineage development. Recently, a mutation was identified in either HDAC1 or HDAC3 that eradicated deacetylase activity but retained decrotonylase activity (“VRPP”). Through this mutation we were able to generate a novel mouse model with Cre-mediated deletion of endogenous HDAC3 and linked re-expression of HDAC3 VRPP. Strikingly, this mouse does not develop colitis, although T cell development is still impaired. Thus, HDAC3 decrotonylase activity alone is sufficient to impede the IBD phenotype. Support by grants from National Institute of Allergy and Infectious Diseases (R01 AI150100)
Beta cell expression of ST8Sia6 protects from autoimmune diabetes in the murine NOD model
Choe, Justin, Rajcula, Matthew, Hammer, Brady, Mai, E, Shapiro, Michael J. , Shapiro, Michael, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 238.13-238.13

10.4049/jimmunol.210.supp.238.13 Get It

Abstract In this study, we leveraged immunomodulatory Siglec-sialic acid interactions to protect beta-cells against autoimmune rejection in Type 1 Diabetes (T1D). Our lab previously demonstrated that the sialyltransferase ST8Sia6 generates ligands that bind the Siglec-E receptor expressed on murine islet-resident macrophages. Here, mice were engineered to express ST8Sia6 in beta cells (βST mice), backcrossed to the non-obese diabetic (NOD) mouse model of T1D, and followed for disease. 60% of female littermates spontaneously developed disease by 300 days, compared to only 6% in female βST mice. Histologic analysis of pancreas sections from non-diabetic βST and littermate mice suggested a similar degree of immune infiltration in early life, but drastically reduced insulitis only in βST mice at later timepoints. This was not due to an absence of autoreactive T cells, as an anti-PD-L1 challenge resulted in similarly rapid induction of disease in both βST and littermate mice. Our genetic model allows for temporal control of ST8Sia6 expression in βST mice using the tet-off system. Treating our mice with doxycycline at 20 weeks of age resulted in persistent protection compared to age matched littermates, while the same treatment at 8 weeks of age led to similar incidence of diabetes between βST mice and littermate controls. Flow cytometric analysis of islet infiltrating immune cells from euglycemic mice at 14 weeks of age demonstrated reductions in short-lived effector CD8 T cells and increased thymically derived Tregs in βST mice compared to littermate controls. These results highlight the therapeutic potential of sialyltransferase mediated immune regulation and present a potential path toward improved curative approaches for T1D. Supported by grants from NIH (5R21AI135858-02, 1F30DK127564)
Accelerated tumorigenesis in a colorectal cancer model in Siglec-E knockout mice
Maniaci, Brandon Lee, Crotts, Sydney B. , Rajcula, Matthew, Hammer, Brady, Mai, Elissa, Friedman, David J. , Hammer, Brady, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 88.12-88.12

10.4049/jimmunol.210.supp.88.12 Get It

Abstract The lifetime risk for colorectal cancer in the United States is approximately 4%. Individuals with Inflammatory Bowel Disease, including Ulcerative Colitis and Crohn’s Disease, have a substantially increased risk of developing colorectal cancer. The mechanisms for accelerated tumorigenesis due to enhanced inflammation are not fully characterized. Siglecs (sialic acid immunoglobulin lectin-like proteins) are a family of inhibitory receptors that are negative regulators of the immune response. Siglec-E is an inhibitory receptor that is expressed by innate immune cells, including monocytes, macrophages, neutrophils and dendritic cells. Interestingly, mice deficient in Siglec-E have accelerated development of tumors and reduced survival in a spontaneous mouse model of colorectal cancer (TS4-cre LSL-KRasG12D APClox468/wt). While tumors develop at approximately six months in mice with Siglec-E, tumors develop at approximately two months in Siglec-E knockout mice. Initial results indicate that Siglec-E knockout mice also have accelerated gut inflammation using the DSS colitis model as compared to WT mice. Current studies are examining inflammation that develops during tumorigenesis in Siglec-E knockout mice. Center for Biomedical Discovery NIH R01 CA243545-01A1 to VSS Mayo Clinic Graduate School of Biomedical Sciences Deans fellowship: Initiative for maximizing student development (IMSD) R25 GM055252-26 Doyon Foundation
ST8Sia6 sialylates CD44 in cancer cells to generate ligands for inhibitory Siglecs
Chen, Alex Shuaibo, Shapiro, Michael J. , Chen, Yin , Friedman, David J. , Saraswat, Mayank , Shapiro, Michael, Wilfahrt, Drew N. , Pandey, Akhilesh , Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 88.14-88.14

10.4049/jimmunol.210.supp.88.14 Get It

Abstract Glycans decorate most proteins and lipids on the cell surface, and glycoproteins serve a critical role in cell-cell communication. The terminal modification of many glycans is a sialic acid. There are twenty different mammalian sialyltransferases, each with a unique specificity. Recently, we demonstrated that the sialyltransferase ST8Sia6, which adds a terminal alpha-2,8 disialic acid to a preexisting sialic acid on cell surface proteins, generates ligands for the inhibitory receptor Siglec-E. In patients, ST8Sia6 overexpression is associated with worse outcome. We have previously shown that ST8sia6 overexpression in a mouse tumor model accelerates tumor growth, dependent upon Siglec-E expression by immune cells. To understand the basis for ST8Sia6 function in tumors, proteomic analysis of murine tumor lines was performed to identify proteins modified by ST8Sia6. Here, we demonstrate that ST8Sia6 sialylates CD44. Siglecs vary significantly between species, with 5 non-conserved Siglecs in mice compared to 10 non-conserved Siglecs in humans. The closest ortholog to Siglec-E in mice is Siglec-7 in humans. We also demonstrate that ST8Sia6 sialylates CD44, generating ligands for Siglec-7. Thus, ST8sia6 has a conserved role in both mice and humans in modifying glycans on CD44 to generate ligands for Siglecs. As CD44 expression on tumors is associated with increased metastasis, we predict that ST8Sia6 may also have a role in this process which is under investigation. Supported by grants from 2T32AI007425-23 to DJF and NIH Glycobiology Common Fund supplement to R01CA243545-01A1 to VSS.
P903: CLINICAL UTILITY OF MONOCLONAL GAMMOPATHY SCREENING IN THE EVALUATION OF PERIPHERAL NEUROPATHY
Maberry, Mackenzie, Smith, Caleb J. , Go, Ronald S.

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e65762dc

10.1097/01.hs9.0000970516.65762.dc Get It